Qiong Zhou
Rui Wang*- Laboratory of Medical Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
A Correction on
Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib
by Zhou Q and Wang R (2025). Front. Cell Dev. Biol. 13:1637767. doi: 10.3389/fcell.2025.1637767
There was a mistake in Figure 3I as published. During the proofing process, the image intended to represent the p65 WB bands from Huh7 cells was mistakenly duplicated, which resulted in the appearance of incorrect images in Figure 3I. We have since conducted a thorough review of all original bands and have confirmed that the original images were accurate and did not contain any duplication. This error was unintentional and occurred during the image compilation. Importantly, this correction does not affect the conclusions drawn from our experiments. The corrected Figure 3 appears below.
Figure 3. The Synergistic Effect of Alisertib and Donafenib on Ferroptosis in Hepatocellular Carcinoma Cells Mediated by the NF-κB Signaling Pathway. (A) PCA analysis of sequencing samples from HCCLM3 cells. (B) Upset plot illustrates the DEGs (p < 0.05, |log2FC|>1) across treatment groups. (C) Volcano plot highlights DEGs significantly in 1555 genes (p < 0.05, |log2FC|>2). (D) KEGG enriched pathways in synergy. (E) Heatmap for PCD scores across HCCLM3. (F) Enrichment scores for PCD in TCGA LIHC samples. (G) Correlation between ferroptosis scores and the NF-κB signaling pathway across 33 tumor types in TCGA and (H) in LIHC from TCGA. (I) NF-κB signaling molecules (p65, IκBα, p-p65, p-IκBα) with quantitative analyses for (K) p65, (L) IκBα, (M) p-p65, (N) p-IκBα, and (O) ratios of p-p65/p65 and (P) p-IkBa/IkBa. (J) cytoplasmic and nuclear p65 expression, including quantitative results for (Q) cytoplasmic p65 and (R) nuclear p65. (S, T) p65 nuclear translocation in HCCLM3 and Huh7 cells. (n = 3, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, non-significant; DFN, Donafenib; Alis, Alisertib).
The original version of this article has been updated.
Generative AI statement
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hepatocellular carcinoma, Donafenib, Alisertib, ferroptosis, NF-κB signaling pathway
Citation: Zhou Q and Wang R (2025) Correction: Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib. Front. Cell Dev. Biol. 13:1685448. doi: 10.3389/fcell.2025.1685448
Received: 13 August 2025; Accepted: 27 August 2025;
Published: 10 September 2025.
Edited and reviewed by:
Junqi Huang, Jinan University, ChinaCopyright © 2025 Zhou and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rui Wang, d2FuZ3J1aTIxOEBuanUuZWR1LmNu